Patents by Inventor Nicholas J. Leeper

Nicholas J. Leeper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION
    Publication number: 20240025966
    Abstract: Methods are provided for the prevention and treatment of vascular inflammation. The methods comprise administering to a human subject an effective dose of an agent that specifically binds to CD47, and reduces one or more indicia of vascular inflammation.
    Type: Application
    Filed: October 21, 2021
    Publication date: January 25, 2024
    Inventors: Nicholas J. Leeper, Irving L. Weissman, Kai-Uwe Jarr, Yoko Kojima
  • COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE
    Publication number: 20220125920
    Abstract: An effective combined dose of an anti-CD47 agent and an anti-TNF? agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Application
    Filed: January 13, 2022
    Publication date: April 28, 2022
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • Combination therapy for treatment of coronary artery disease
    Patent number: 11253588
    Abstract: An effective combined dose of an anti-CD47 agent and an anti-TNF agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: February 22, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • TARGETING ANEURYSM DISEASE BY MODULATING PHAGOCYTOSIS PATHWAYS
    Publication number: 20210095025
    Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 1, 2021
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • Targeting aneurysm disease by modulating phagocytosis pathways
    Patent number: 10822411
    Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: November 3, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • Modulation of efferocytosis pathways for treatment of atherosclerotic disease
    Patent number: 10329354
    Abstract: Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 25, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE
    Publication number: 20180028651
    Abstract: An effective combined dose of an anti-CD47 agent and an anti-TNF agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Application
    Filed: February 25, 2016
    Publication date: February 1, 2018
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • TARGETING ANEURYSM DISEASE BY MODULATING PHAGOCYTOSIS PATHWAYS
    Publication number: 20170291945
    Abstract: In the methods of the invention, an agent that increases phagocytosis and/or efferocytosis of cellular components of coronary plaque is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce aneurysm disease in the individual.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 12, 2017
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • MODULATION OF EFFEROCYTOSIS PATHWAYS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE
    Publication number: 20160194406
    Abstract: Smooth muscle cells (SMC) from subjects carrying at least one 9p21 risk factor, can be resistant to efferocytosis, leading to the retention of such cells in the necrotic core of atherosclerotic plaque. In the methods of the invention, an agent that increases efferocytosis of cellular components of coronary plaque, including efferocytosis of apoptotic smooth muscle cells, is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.
    Type: Application
    Filed: September 15, 2014
    Publication date: July 7, 2016
    Inventors: Nicholas J. Leeper, Irving L. Weissman
  • BIOMARKERS FOR PREDICTING MAJOR ADVERSE EVENTS
    Publication number: 20140187519
    Abstract: Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 3, 2014
    Applicant: The Board Of Trustees Of The Leland Stanford Junior University
    Inventors: John P. Cooke, Nicholas J. Leeper, Kevin Nead